Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.

Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, Perry CR, Raychaudhuri A, Dumont EF, Huang J, Hook EW 3rd, Miller LA.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01221-18. doi: 10.1128/AAC.01221-18. Print 2018 Dec.

2.

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.

Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, Perry CR, Raychaudhuri A, Scangarella-Oman NE, Hossain M, Dumont EF.

Clin Infect Dis. 2018 Aug 1;67(4):504-512. doi: 10.1093/cid/ciy145.

3.

Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE, Sader HS.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00468-17. doi: 10.1128/AAC.00468-17. Print 2017 Jul.

4.

Analysis of MIC and Disk Diffusion Testing Variables for Gepotidacin and Comparator Agents against Select Bacterial Pathogens.

Koeth LM, DiFranco-Fisher JM, Scangarella-Oman NE, Miller LA.

J Clin Microbiol. 2017 Jun;55(6):1767-1777. doi: 10.1128/JCM.02366-16. Epub 2017 Mar 22.

5.

In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02047-16. doi: 10.1128/AAC.02047-16. Print 2017 Mar.

6.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
7.

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.

Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4404-6. doi: 10.1128/AAC.00527-16. Print 2016 Jul.

8.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15.

9.
10.

Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.

O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR.

Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. doi: 10.1128/AAC.03774-14. Epub 2014 Oct 27.

11.

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.

Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN.

J Clin Microbiol. 2014 Jul;52(7):2629-32. doi: 10.1128/JCM.00656-14. Epub 2014 Apr 23.

12.

Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.

Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN.

J Clin Microbiol. 2011 Nov;49(11):3928-30. doi: 10.1128/JCM.01213-11. Epub 2011 Sep 14.

13.

Microbiological profile of a new topical antibacterial: retapamulin ointment 1%.

Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):269-79. doi: 10.1586/eri.09.7. Review.

PMID:
19344241

Supplemental Content

Loading ...
Support Center